Elzovantinib

Overview

Elzovantinib (TPX-0022) is an oral-active inhibitor of SRC , MET and c-FMS , with IC 50 values of 0.12 nM, 0.14 nM and 0.76 nM for SRC , MET and c-FMS respectively.

Application

Products | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Gastric Cancer | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Pain | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > Src | Products > Signaling Pathways > c-Met/HGFR | Products > Signaling Pathways > c-Fms

Product Information

• Catalog No.: HY-111787
• CAS No.: 2271119-26-5
• Molecular Formula: C20H20FN7O2
• Molecular Weight: 409.42
• Purity: 99.93%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.08 mg/mL (5.08 mM); Clear solution
• Availability: In-stock

Source

Original product source